VSTM — Verastem, Inc.
Is VSTM overbought or oversold? Here is the current MarketMoodz read.
Verastem, Inc. (VSTM) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $7.70. The rating moved from Neutral to Strong Oversold on November 6, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$7.70
- Last changeMoved from Neutral to Strong Oversold on November 6, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Verastem, Inc. is a clinical-stage biotech whose near-term value is driven primarily by pipeline milestones and financing dynamics. The available information does not include recent filings or detailed financials, creating uncertainty around cash runway and dilution risk. Broader sector flows currently favor large-cap pharmaceuticals and defensive names, which can constrain speculative capital for smaller biotechs. Key upside catalysts would be positive clinical readouts, regulatory progress, or strategic partnerships; downside scenarios include trial setbacks, regulatory hurdles, or the need for dilutive financing. Given the profile, investors should monitor upcoming program milestones, company cash disclosures, and any financing announcements closely.
Key factors
- Clinical-stage biotech profile with value tied to pipeline outcomes and regulatory readouts
- Limited public financial disclosure in the provided data set — cash runway and revenue/expense visibility unclear
- High R&D burn typical of small-cap oncology/biotech companies increases near-term financing need
- Sector flows favoring large-cap pharma and defensive exposure reduce speculative capital available to small biotechs
- Convertible-debt/dilution pressures in the broader diagnostics/biotech market raise the probability of equity dilution or financing at unfavorable terms
- Potential catalysts include clinical trial readouts, regulatory interactions, or partnership/licensing announcements
- Low social sentiment and lack of recent EDGAR/filing detail in the dataset increase uncertainty about market perception and insider activity
- Competitive landscape and reimbursement dynamics for oncology therapeutics could materially affect commercial prospects if programs advance
Risks
- Clinical trial failure or negative interim data that would materially reduce valuation
- Regulatory setback or requirement for additional studies delaying timelines
- Insufficient cash runway leading to dilutive financing (equity or convertibles) at unattractive terms
- Intense competition from larger pharma/biotech entrants with deeper resources and established commercial channels
- Low trading liquidity and high share-price volatility amplifying downside on adverse news
- General rotation into large-cap defensive healthcare names could restrict capital flows into small-cap biotechs
- Unclear commercialization pathway or payer resistance could impair future revenue potential
- Lack of visible near-term revenue streams increases dependency on external funding
See today's live rating, score and targets
Members see the live hourly rating for VSTM — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.